Q2 2026 VolitionRX Ltd Earnings Call Transcript
Key Points
- VolitionRX Ltd (VNRX) reported strong progress in its Nu.Q Nets sepsis program, including a lateral flow prototype assay that can detect nucleosomes from a finger prick sample, potentially expanding its total addressable market significantly.
- The company announced a new collaboration with Sysmex Corporation, a global leader in in vitro diagnostics, to develop Nu.Q-NET assays for diseases associated with NETosis, adding to its existing partnership with Werfen.
- VolitionRX Ltd (VNRX) achieved a major milestone with the publication of a peer-reviewed paper detailing its Capture-Seek technology, which isolates >99% pure circulating tumor-associated DNA, a novel approach to liquid biopsy.
- The company's Nu.Q Vet feline lymphoma assay demonstrated high accuracy (97% specificity, 86% sensitivity) in detecting the most common cancer in cats, with publication expected to unlock a $5 million milestone payment.
- VolitionRX Ltd (VNRX) is supplying its automated analyzer to the Mayo Clinic for trauma research, following compelling data showing Nu.Q NETs levels are elevated in trauma patients and significantly higher in those with complications.
- The company reduced total operating expenses by 32% year-over-year in Q2 2026, reflecting successful cost reduction measures and a 27% reduction in headcount.
- VolitionRX Ltd (VNRX) reported flat Q2 2026 revenue of approximately $0.4 million, broadly in line with the same period in 2025, due to lower services revenue from Nu.Q Discover and the lumpy nature of project delivery.
- The company's net loss for Q2 2026 increased to $7.3 million from $6.3 million in the prior year, primarily due to non-cash accounting charges of approximately $3 million related to the Lind convertible notes.
- VolitionRX Ltd (VNRX) continues to face significant cash burn, with net cash used in operating activities of $5.2 million in Q2 2026, and cash reserves remain low at approximately $2.8 million at quarter end.
- The publication of the feline lymphoma paper, which is expected to trigger a $5 million milestone payment, is taking longer than hoped due to the peer review process.
- The company's revenue remains highly unpredictable and lumpy, with management explicitly stating they will not provide revenue guidance for 2026, reflecting ongoing uncertainty in commercialization.
- VolitionRX Ltd (VNRX) faces regulatory and reimbursement risks, particularly for its Nu.Q lung cancer test in France, where the process is complex and not guaranteed to succeed.
Hello, everyone, and thank you for standing by. Welcome to Volition Rx Limited's Second Quarter 2026 Earnings Conference Call.
During today's presentation, all parties will be in a listen-only mode.
Following the presentation, the conference call will be open for questions.
If you have a question, please press the star key followed by the number 1 on your touch-tone phone.
If you would like to withdraw your question, please press the star key followed by the number 2.
If you're using speaker equipment, please lift the handset before making your selections.
This conference call is being recorded today, August 14, 2026.
I'd now like to turn the conference call over to Louise Batchelor, Group Chief Marketing and Communications Officer.
Welcome, everyone, to today's earnings conference call for Vilishin RX Limited. Before we begin, I'd like to remind everyone that some of the information discussed on this
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
